Breast cancer and cardiovascular health

Eur Heart J. 2024 Nov 7;45(41):4366-4382. doi: 10.1093/eurheartj/ehae637.

Abstract

Modern cancer therapies greatly improve clinical outcomes for both early and advanced breast cancer patients. However, these advances have raised concerns about potential short- and long-term toxicities, including cardiovascular toxicities. Therefore, understanding the common risk factors and underlying pathophysiological mechanisms contributing to cardiovascular toxicity is essential to ensure best breast cancer outcomes. While cardio-oncology has emerged as a sub-speciality to address these challenges, it is essential that all cardiologists recognize and understand the cardiovascular consequences of cancer therapy. This review aims to provide a comprehensive overview of the potential adverse cardiovascular effects associated with modern breast cancer therapies. A preventive, diagnostic, and therapeutic workflow to minimize the impact of cardiovascular toxicity on patient outcomes is presented. Key aspects of this workflow include regular monitoring of cardiovascular function, early detection and management of cancer therapy-related cardiovascular toxicities, and optimization of cardiovascular risk factor control. By highlighting the gaps in knowledge in some areas, this review aims to emphasize the critical role of cardio-oncology research in ensuring the holistic well-being of patients with breast cancer.

Keywords: Breast cancer; Cardio-oncology; Cardiotoxicity; Chemotherapy; Exercise; Prevention; Radiotherapy; Women health.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Breast Neoplasms* / therapy
  • Cardiotoxicity / etiology
  • Cardiotoxicity / prevention & control
  • Cardiovascular Diseases* / etiology
  • Cardiovascular Diseases* / prevention & control
  • Female
  • Humans
  • Risk Factors

Substances

  • Antineoplastic Agents